Osteogenic Effects in Human Mesenchymal Stem Cells Enhanced by Wnt Signaling

Osteogenic Effects in Human Mesenchymal Stem Cells Enhanced by Wnt Signaling/Hydroxyapatite Nanoparticles--Comparisons Between Non-viral and Viral Administration in Tissue Engineered Bone Regeneration

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01323894

Enrollment

Registered

2011-03-28

Start date

2011-08-31

Completion date

2013-07-31

Last updated

2016-06-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Primary Disease

Brief summary

The first year purpose: The best concentration of canonical Wnt3a will be investigated in promoting the osteoblastogenesis of human mesenchymal stem cells.

Detailed description

Our previous work is investigating the viral (Adv-BMP-2) administration for the development of a model to generate bones for possible use in clinical settings; the non-viral and viral administrations will be compared for best osteogenesis effects. The first year purpose: The best concentration of canonical Wnt3a will be investigated in promoting the osteoblastogenesis of human mesenchymal stem cells.

Interventions

None listed

Eligibility

Sex/Gender

ALL

Age

10 Years to 80 Years

Healthy volunteers

Inclusion criteria

* age above 10 years old * The patients require surgery ner iliac or abdomen areas

Exclusion criteria

* age below 10 years old

Design outcomes

Primary

Measure	Time frame	Description
Osteogenic Effects in Human Mesenchymal Stem Cells Enhanced by Wnt Signaling/Hydroxyapatite Nanoparticles--Comparisons between Non-viral and Viral administration in Tissue Engineered Bone Regeneration	2 years	August 2011-July 2013

Countries

Taiwan

Outcome results